Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pyxis Oncology, Inc.

0.9459
-0.0741-7.26%
Volume:261.25K
Turnover:248.63K
Market Cap:58.26M
PE:-0.71
High:1.00
Open:0.9600
Low:0.9200
Close:1.02
Loading ...

Pyxis Oncology’s Strategic Focus on PYX-201 and Collaboration with Merck Drives Buy Rating

TIPRANKS
·
21 Dec 2024

Strategic Focus on PYX-201 Drives Positive Buy Rating for Pyxis Oncology

TIPRANKS
·
21 Dec 2024

Pyxis Oncology price target lowered to $5 from $7 at H.C. Wainwright

TIPRANKS
·
20 Dec 2024

Pyxis Oncology, Inc. : H.c. Wainwright Cuts Target Price to $5 From $7

THOMSON REUTERS
·
20 Dec 2024

Pyxis Oncology Price Target Cut to $8.00/Share From $10.00 by RBC Capital

Dow Jones
·
20 Dec 2024

RBC Cuts Price Target on Pyxis Oncology to $8 From $10, Keeps Outperform, Speculative Risk

MT Newswires Live
·
20 Dec 2024

Pyxis Oncology price target lowered to $8 from $10 at RBC Capital

TIPRANKS
·
20 Dec 2024

Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program

Dow Jones
·
20 Dec 2024

Pyxis Oncology to Focus Resources on Lead Clinical Program PYX-201

MT Newswires Live
·
20 Dec 2024

BRIEF-Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources On Its Lead Clinical Program, Pyx-201

Reuters
·
20 Dec 2024

Pyxis Oncology to prioritize PYX-201, suspends investment in PYX-106

TIPRANKS
·
20 Dec 2024

Pyxis Oncology Shares up 5.2% at $1.62 After the Bell Following Announcement of Portfolio Prioritization

THOMSON REUTERS
·
20 Dec 2024

Refile- Pyxis Oncology- Company to Focus on Advancing Lead Asset, Pyx-201 (Adds Dropped Words)

THOMSON REUTERS
·
20 Dec 2024

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on Its Lead Clinical Program, Pyx-201

THOMSON REUTERS
·
20 Dec 2024

Pyxis Oncology Inc - - Company

THOMSON REUTERS
·
20 Dec 2024

Pyxis Oncology Inc - Current Cash Runway Expected to Fund Development Into 2H 2026

THOMSON REUTERS
·
20 Dec 2024

CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares

Simply Wall St.
·
01 Dec 2024

Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$142m market cap decline as longer-term profits stay in the green

Simply Wall St.
·
27 Nov 2024

Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings

Benzinga
·
22 Nov 2024

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More

Zacks
·
22 Nov 2024